1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Checkpoint Inhibitor Biologics CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Checkpoint Inhibitor Biologics CDMO Market, by Service Type
8.1.1. Cell Line Development
8.1.1.1. Market Revenue and Forecast
8.1.2. Process Development
8.1.2.1. Market Revenue and Forecast
8.1.3. Analytical and Quality Control
8.1.3.1. Market Revenue and Forecast
8.1.4. Commercial Manufacturing
8.1.4.1. Market Revenue and Forecast
8.1.5. Fill-Finish Services
8.1.5.1. Market Revenue and Forecast
9.1. Checkpoint Inhibitor Biologics CDMO Market, by Technology Platform
9.1.1. Mammalian Cell Culture
9.1.1.1. Market Revenue and Forecast
9.1.2. Microbial Fermentation
9.1.2.1. Market Revenue and Forecast
9.1.3. Cell-Free Systems
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Checkpoint Inhibitor Biologics CDMO Market, by Drug Class
10.1.1. Monoclonal Antibodies
10.1.1.1. Market Revenue and Forecast
10.1.2. Bispecific Antibodies
10.1.2.1. Market Revenue and Forecast
10.1.3. Fusion Proteins
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. Checkpoint Inhibitor Biologics CDMO Market, by End-User
11.1.1. Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Firms
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic and Research Institutions
11.1.3.1. Market Revenue and Forecast
11.1.4. Others
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service Type
12.1.2. Market Revenue and Forecast, by Technology Platform
12.1.3. Market Revenue and Forecast, by Drug Class
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service Type
12.1.5.2. Market Revenue and Forecast, by Technology Platform
12.1.5.3. Market Revenue and Forecast, by Drug Class
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service Type
12.1.6.2. Market Revenue and Forecast, by Technology Platform
12.1.6.3. Market Revenue and Forecast, by Drug Class
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service Type
12.2.2. Market Revenue and Forecast, by Technology Platform
12.2.3. Market Revenue and Forecast, by Drug Class
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service Type
12.2.5.2. Market Revenue and Forecast, by Technology Platform
12.2.5.3. Market Revenue and Forecast, by Drug Class
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service Type
12.2.6.2. Market Revenue and Forecast, by Technology Platform
12.2.6.3. Market Revenue and Forecast, by Drug Class
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service Type
12.2.7.2. Market Revenue and Forecast, by Technology Platform
12.2.7.3. Market Revenue and Forecast, by Drug Class
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service Type
12.2.8.2. Market Revenue and Forecast, by Technology Platform
12.2.8.3. Market Revenue and Forecast, by Drug Class
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service Type
12.3.2. Market Revenue and Forecast, by Technology Platform
12.3.3. Market Revenue and Forecast, by Drug Class
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service Type
12.3.5.2. Market Revenue and Forecast, by Technology Platform
12.3.5.3. Market Revenue and Forecast, by Drug Class
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service Type
12.3.6.2. Market Revenue and Forecast, by Technology Platform
12.3.6.3. Market Revenue and Forecast, by Drug Class
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service Type
12.3.7.2. Market Revenue and Forecast, by Technology Platform
12.3.7.3. Market Revenue and Forecast, by Drug Class
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service Type
12.3.8.2. Market Revenue and Forecast, by Technology Platform
12.3.8.3. Market Revenue and Forecast, by Drug Class
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service Type
12.4.2. Market Revenue and Forecast, by Technology Platform
12.4.3. Market Revenue and Forecast, by Drug Class
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service Type
12.4.5.2. Market Revenue and Forecast, by Technology Platform
12.4.5.3. Market Revenue and Forecast, by Drug Class
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service Type
12.4.6.2. Market Revenue and Forecast, by Technology Platform
12.4.6.3. Market Revenue and Forecast, by Drug Class
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service Type
12.4.7.2. Market Revenue and Forecast, by Technology Platform
12.4.7.3. Market Revenue and Forecast, by Drug Class
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service Type
12.4.8.2. Market Revenue and Forecast, by Technology Platform
12.4.8.3. Market Revenue and Forecast, by Drug Class
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service Type
12.5.2. Market Revenue and Forecast, by Technology Platform
12.5.3. Market Revenue and Forecast, by Drug Class
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service Type
12.5.5.2. Market Revenue and Forecast, by Technology Platform
12.5.5.3. Market Revenue and Forecast, by Drug Class
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service Type
12.5.6.2. Market Revenue and Forecast, by Technology Platform
12.5.6.3. Market Revenue and Forecast, by Drug Class
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Lonza Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. WuXi AppTec
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Samsung Biologics
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. WuXi Biologics
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Boehringer Ingelheim
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Roche
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Sanofi
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GSK
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Abbott
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
